Latest news

• Novartis bags new breakthrough status for Kisqali in breast cancer

  show that a CDK4/6 inhibitor can have a benefit in this setting. ... Meanwhile Novartis is trying to keep its new drug ahead of Eli Lilly’s CDK4/6 inhibitor Verzenio (abemaciclib), which was approved in the US - its first market - last September.

• Novartis raises pressure in Pfizer’s Ibrance with new Kisqali data

  New phase III data for Novartis’CDK4/6 inhibitor Kisqali has shown that the drug is effective in tackling breast cancer in younger women. ... Novartis is currently a little ahead of Eli Lilly, whose CDK4/6 inhibitor Verzenio (abemaciclib) was approved

• Lilly's abemaciclib data leaves potential uncertain

  The MONARCH 3 trial was reported at the European Society of Medical Oncology (ESMO) conference in Madrid over the weekend, and showed that the CDK4/6 inhibitor prolonged progression-free survival ... This is a clinically relevant proportion of patients

• Dismay as NICE turns down first-line use of AZ's Faslodex

  trial, which showed that the drug was superior to the widely-used aromatase inhibitor anastrozole as a first-line treatment. ... While other drugs such as Pfizer's CDK4/6 inhibitor Ibrance (palbociclib) and Novartis' rival Kisqali (ribociclib) "may yet

• Novartis claims EU approval for breast cancer drug Kisqali

  Novartis claims EU approval for breast cancer drug Kisqali. Firm's CDK4/6 inhibitor can now challenge Pfizer's Ibrance in Europe. ... Novartis can now challenge Pfizer's blockbuster breast cancer drug Ibrance in Europe after gaining approval for its